Site Editor

Sandy Srinivas, MD


Health-Related Quality of Life Data From PROpel on Abiraterone Plus Olaparib in Prostate Cancer

By: Chris Schimpf, BS
Posted: Friday, July 14, 2023

Many patients receiving treatment for metastatic castration-resistant prostate cancer not only derived clinical benefit from the combination of abiraterone and olaparib, but also maintained a similar health-related quality of life to standard-of-care abiraterone alone, according to Antoine Thiery-Vuillemin, MD, PhD, of Centre Hospitalier Régional Universitaire de Besançon, France, and colleagues. According to phase III PROpel trial data presented at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting (Abstract 5012), patients who received the combination experienced prolonged radiographic progression–free survival and no clinically meaningful difference in health-related quality of life, versus those who received abiraterone with a placebo. The final overall survival data from this trial, reinforcing the potential of this regimen in this patient population, were previously presented at the 2023 ASCO Genitourinary Cancer Symposium.

In the randomized, double-blind trial of 796 patients receiving first-line treatment for metastatic castration-resistant prostate cancer, 399 received abiraterone with olaparib, and 397 received abiraterone with a placebo. Health-related quality of life was assessed using the Functional Assessment of Cancer Therapy–Prostate questionnaire, the Brief Pain Inventory-Short Form, and the analgesic quantification algorithm to gauge patients’ opiate analgesic use.

In addition to no clinically meaningful difference in health-related quality of life between the two groups, the researchers also observed no meaningful difference in the time to pain progression as well as in the time to first symptomatic skeletal-related event. At 24 months, 76.9% of patients who received abiraterone plus olaparib had not experienced a pain progression event, and 86.1% had not experienced a symptomatic skeletal-related event, versus 77.2% and 82.2% in the abiraterone plus placebo group. At 36 months, the rates were 70.7% and 80.8% versus 71% and 78.5%.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.